OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Neurology is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
The deltoid muscle and the pattern of paresis in ALS	229
Neuromyelitis optica spectrum disorder with a familial Mediterranean fever gene E84K mutation	210
Tacrolimus-induced Parkinsonism	154
Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod	106
The DeMyers: Marian (1922–2012) and William (1924–2008)	101
Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study	99
Tourette syndrome: effects of acetyl-leucine in two individuals	94
Phenotype-driven reanalysis reveals five novel pathogenic variants in 40 exome-negative families with Charcot–Marie–Tooth Disease	89
Dizziness and spatial disorientation in patients with transient global amnesia: clinical and vestibular correlates	87
Stroke frequency, associated factors, and clinical features in primary systemic vasculitis: a multicentric observational study	81
Hashimoto’s encephalopathy with diffuse leukoencephalopathy: serial MRI and gait analysis	81
Assessment of cognitive function, structural brain changes and fatigue 6 months after treatment of neuroborreliosis	79
Nomograms integrating cortical morphometric metrics with 3D multi-parametric MRI radiomics for predicting disability progression and cognitive worsening in relapsing–remitting multiple sclerosis: a mu	79
Performance of blind source separation in localizing seizure onset from routine scalp-EEG	79
Correction to: Synergistic effects of vagus nerve stimulation and antiseizure medication	77
Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy	72
Effects of deep brain stimulation on non-motor symptoms in Parkinson’s disease: insights from longitudinal studies using consistent evaluation scales	72
Different patterns of acute saccadic response to levodopa in de novo Parkinson’s disease	72
Incidence of Guillain–Barré syndrome in Cuba before and during the Oropouche virus emergency, 2018–2024	69
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study	65
Neurological manifestation of HEV infection: still a rare disease entity?	65
Cross-sectional brain volumetric measures and disability outcomes in relapsing–remitting multiple sclerosis	62
Dystonia management across Europe within ERN-RND: current state and future challenges	61
Interpretable deep learning survival predictions in sporadic Creutzfeldt–Jakob disease	60
Improving conscientiousness through a smartphone app and telecoaching intervention: insights from multiple sclerosis and healthy aging samples	60

Prevalence of infratentorial superficial siderosis in a large general population sample from the UK Biobank	57
Prevalence of hereditary transthyretin amyloidosis in CIDP patients with red flags: a multicenter genetic screening and misdiagnosis analysis	57
Primary progressive aphasia: six questions in search of an answer	56
Explaining recovery from coma with multimodal neuroimaging	56
Exploring epigenetic modifications as potential biomarkers and therapeutic targets in amyotrophic lateral sclerosis	56
Ocrelizumab in early relapsing–remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort	56
A real-world study on the utility of regular rituximab treatment for neuromyelitis optica spectrum disorder	54
Historical and current issues in HIV encephalitis, and the role of neuropathology in HIV disease: a pathological perspective	53
Complications of reversible cerebral vasoconstriction syndrome in relation to age	53
Microstructural characterization of multiple sclerosis lesion phenotypes using multiparametric longitudinal analysis	53
Disrupted and reorganized connectivity of brain networks in multiple sclerosis: a systematic review and meta-analysis of resting-state functional MRI	52
International survey on the implementation of the European and American guidelines on disorders of consciousness	52
Tau levels in platelets isolated from Huntington’s disease patients serve as a biomarker of disease severity	52
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension	51
Long-term outcome after decompressive hemicraniectomy for malignant middle cerebral artery infarction	51
Triple-crush mechanism in multiple sclerosis-associated trigeminal neuralgia	50
Genetic forms of tauopathies: inherited causes and implications of Alzheimer’s disease-like TAU pathology in primary and secondary tauopathies	49
Plasma p-tau217 best captures early longitudinal cognitive changes in subjective cognitive decline compared with p-tau181 and NfL	49
Keeping an eye on Parkinson’s disease: color vision and outer retinal thickness as simple and non-invasive biomarkers	48
A decision aid is not the quick fix for improving shared decision-making in advanced Parkinson’s disease: results of a mixed methods feasibility study	48
SARA captures disparate progression and responsiveness in spinocerebellar ataxias	48
CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective	48
Pallidal deep brain stimulation for patients with myoclonus-dystonia without SGCE mutations	48